ALB and type 2 diabetes nephropathy: Our present observations suggest febuxostat suppresses urinary albumin and glomerular injury at early stages of type 2 diabetic nephropathy, i.e., at the stage when inflammatory cytokines, such as IL-6 [32] and MCP-1, are secreted [33].